Company profile: InCarda Therapeutics
1.1 - Company Overview
Company description
- Provider of inhalation-route therapies for cardiovascular conditions, developing an orally inhaled flecainide to treat acute episodes of paroxysmal atrial fibrillation (PAF) using approved drugs in a new dosing method, and advancing additional cardiology programs addressing unmet needs toward clinical development.
Products and services
- Additional Cardiology Programs: Architects therapies addressing unmet cardiovascular needs across diseases, advancing toward clinical development, clinical-development-focused
- Inhalation-Based Cardiovascular Therapeutics Approach: Engineers a novel method to treat cardiovascular conditions via inhalation, inhalation-route
- Orally Inhaled Flecainide for PAF: Delivers approved flecainide inhalation treating acute PAF episodes using new dosing method, development-stage
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to InCarda Therapeutics
Cardiokine
HQ: United States
Website
- Description: Provider of specialty pharmaceutical development for the prevention and treatment of cardiovascular diseases, including lixivaptan, an orally active vasopressin receptor antagonist for congestive heart failure patients with hyponatremia.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cardiokine company profile →
Shockwave Medical
HQ: United States
Website
- Description: Provider of intravascular lithotripsy (IVL) solutions for treating calcified coronary and peripheral arteries, including balloon dilatation catheters with lithotripsy electrodes that increase lesion compliance prior to low‑pressure dilation to limit injury to healthy tissue. Offerings include Shockwave C2+, L6, M5+, S4 IVL catheters, the IVL Generator, and the Shockwave Reducer System for refractory angina pectoris.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Shockwave Medical company profile →
Rapidscan Pharma
HQ: United States
Website
- Description: Provider of regadenoson, a pharmacological stress agent used in the diagnosis and risk stratification of cardiovascular disease, with licensed rights to sell in Europe and select territories.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Rapidscan Pharma company profile →
CardioInsight
HQ: United States
Website
- Description: Provider of electrocardiographic mapping technology that non-invasively generates 3D images of the heart's electrical activity to help treat arrhythmias and congestive heart failure, and cardiac electrophysiology systems for atrial fibrillation, including noninvasive 3D mapping, pulsed field ablation, cryoballoon, temperature-controlled RF ablation, and cryoablation catheters.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CardioInsight company profile →
CiVi Biopharma
HQ: United States
Website
- Description: Provider of clinical-stage biotechnology research and development focused on novel cardiovascular therapies, including CiVi 008, an oral PCSK9-targeting treatment to lower LDL cholesterol and prevent atherosclerotic cardiovascular disease, and CiVi 030, an intravenous iloprost formulation for severe frostbite with vasodilator, platelet inhibitor, anti-inflammatory, and anti-fibrotic effects.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CiVi Biopharma company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for InCarda Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to InCarda Therapeutics
2.2 - Growth funds investing in similar companies to InCarda Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for InCarda Therapeutics
4.2 - Public trading comparable groups for InCarda Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →